---
document_datetime: 2024-11-12 17:17:52
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/posaconazole-ahcl-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: posaconazole-ahcl-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.6656925
conversion_datetime: 2025-12-27 22:06:05.813803
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Posaconazole AHCL

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                      |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------|
| IB/0014              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 08/11/2024                          |                                             | SmPC and PL                      |                                                              |
| R/0011               | Renewal of the marketing authorisation.                                                                                                                                                        | 22/02/2024                          | 09/04/2024                                  | SmPC, Annex                      | Based on the review of data on quality, safety and efficacy, |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                |            |            | II and PL              | the CHMP considered that the benefit-risk balance of Posaconazole AHCL in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0012/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/02/2024 | 09/04/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                      |
| IA/0010/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                              | 09/10/2023 | 29/02/2024 | Annex II and PL        |                                                                                                                                                                                                                      |
| IA/0008   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                  | 21/12/2022 | 29/02/2024 | SmPC                   |                                                                                                                                                                                                                      |
| IB/0007/G | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                  | 01/08/2022 | 29/02/2024 | SmPC and PL            |                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | the RMP - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                           |            |            |                 | authorisation, including   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------|
| IA/0006   | A.7 - Administrative change - Deletion of sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/01/2022 | 15/07/2022 | Annex II and PL | manufacturing              |
| IB/0005/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 26/01/2022 | n/a        |                 |                            |

<div style=\"page-break-after: always\"></div>

|           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                |            |            |             |                                                                                                                                                                                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0004 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                   | 19/10/2021 | 15/07/2022 | SmPC and PL |                                                                                                                                                                                                                                                                                                         |
| IB/0003   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 11/08/2021 | 15/07/2022 | SmPC and PL | To update section 4.8 of the SmPC in line with the reference product with 'pseudoaldosteronism' as an adverse event in post-marketing experience, following a review of six case reports in the scientific literature of concurrent hypertension and hypokalemia in patients treated with posaconazole. |
| IA/0002   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                   | 12/12/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                         |
| II/0001   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                  | 05/12/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                         |